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Phthalates are a class of organic chemicals that 
have been used as plasticizers for polyvinyl-
chloride formulations since the 1930s. These 
chemicals have been widely used in food pack-
aging, medical devices and medications, toys, 
and building materials, as well as cosmetics 
and personal care products commonly used 
by women, such as perfume, lotion, and nail 
polish (Blount et al. 2000b). There is increas-
ing concern that phthalates may have negative 
effects on human fertility and reproductive 
health, although there have been few studies 
on this topic. Moreover, most of the human 
studies suggesting an effect of phthalates on 
reproductive health have focused on males 
and have found deleterious effects on testicu-
lar function and spermatogenesis (Hauser and 
Calafat 2005).
Several studies in experimental animals 
suggest that phthalates possess endocrine-
disrupting properties and can adversely 
affect reproductive function by antagonizing 
or altering the effects of endogenous sex ste-
roid hormones (Agarwal et al. 1985, 1989; 
Arcadi et al. 1998; Berman and Laskey 1993; 
Davis et al. 1994a, 1994b; Lamb et al. 1987; 
Laskey and Berman 1993; Lovekamp and 
Davis 2001), and an emerging literature has 
begun to identify potential effects on female 
animals. Specifically, studies of sexually 
mature rats have found that exposure to di(2-
ethylhexyl) phthalate (DEHP) and one of its 
metabolites, mono(2-ethylhexyl) phthalate 
(MEHP), is associated with smaller preovula-
tory follicles, anovulation or delayed ovulation, 
longer estrous cycles, decreased synthesis of 
estradiol, decreased serum progesterone levels, 
and increased serum follicle-stimulating hor-
mone (FSH) levels (Davis et al. 1994a, 1994b; 
Lovekamp and Davis 2001). In addition, stud-
ies in pregnant and pseudopregnant rats have 
found associations between exposures to dibu-
tyl phthalate (DBP) and benzyl butyl phthalate 
(BzBP) and impaired implantation in mated 
females (Ema et al. 1998, 2000), suggesting 
a possible link between phthalates and altera-
tions in the endogenous hormonal milieu. In 
these studies, monobutyl phthalate (MBP), the 
main metabolite of DBP, and other phthalate 
metabolites, including monomethyl phthalate, 
monoethyl phthalate (MEP), monopropyl 
phthalate, and monopentyl phthalate, had no 
effect on estradiol synthesis (Lovekamp and 
Davis 2001).
Given that some phthalates have anti-
estrogenic activities (Davis et al. 1994a, 
1994b; Lamb et al. 1987), and some have been 
shown to have weak estrogenic activity in vitro 
(Harris et al. 1997; Picard et al. 2001), there 
is biologic plausibility for an effect of phtha-
lates on the incidence of hormone-responsive 
conditions such as endometriosis and uterine 
leiomyomata (fibroids). Endometriosis and 
uterine leiomyomata are common disorders 
among reproductive-age women and are asso-
ciated with considerable morbidity, includ-
ing pelvic pain, menorrhagia, and infertility 
(Eskenazi and Warner 1997; Schwartz et al. 
2000; Velebil et al. 1995). Endometriosis is 
characterized by growth beyond or outside the 
uterus of tissue resembling the endometrium. 
Uterine leiomyomata are benign neoplasms 
composed of smooth muscle cells, growing 
within or around the myometrium. Prevalence 
estimates of clinically relevant endometriosis 
and leiomyomata in premenopausal women 
are approximately 10% and 30%, respectively 
(Baird et al. 2003; Missmer and Mohllajee 
2008; Schwartz et al. 2000). Both conditions 
are leading indications for hysterectomy in 
the United States (Farquhar and Steiner 2002; 
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Background: Phthalates are ubiquitous chemicals used in consumer products. Some phthalates are 
reproductive toxicants in experimental animals, but human data are limited.
oBjective: We conducted a cross-sectional study of urinary phthalate metabolite concentrations 
in relation to self-reported history of endometriosis and uterine leiomyomata among 1,227 women 
20–54 years of age from three cycles of the National Health and Nutrition Examination Survey 
(NHANES), 1999–2004.
Methods: We examined four phthalate metabolites: mono(2-ethylhexyl) phthalate (MEHP), 
monobutyl phthalate (MBP), monoethyl phthalate (MEP), and monobenzyl phthalate (MBzP). 
From the last two NHANES cycles, we also examined mono(2-ethyl-5-hydroxyhexyl) phthalate 
(MEHHP) and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP). We used logistic regression to esti-
mate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for potential confounders.
results: Eighty-seven (7%) and 151 (12%) women reported diagnoses of endometriosis and 
leiomyomata, respectively. The ORs comparing the highest versus lowest three quartiles of urinary 
MBP were 1.36 (95% CI, 0.77–2.41) for endometriosis, 1.56 (95% CI, 0.93–2.61) for leiomyo-
mata, and 1.71 (95% CI, 1.07–2.75) for both conditions combined. The corresponding ORs for 
MEHP were 0.44 (95% CI, 0.19–1.02) for endometriosis, 0.63 (95% CI, 0.35–1.12) for leio-
myomata, and 0.59 (95% CI, 0.37–0.95) for both conditions combined. Findings for MEHHP and 
MEOHP agreed with findings for MEHP with respect to endometriosis only. We observed null 
associations for MEP and MBzP. Associations were similar when we excluded women diagnosed 
> 7 years before their NHANES evaluation.
conclusion: The positive associations for MBP and inverse associations for MEHP in relation to 
endometriosis and leiomyomata warrant investigation in prospective studies.
key words: dibutyl phthalate, di(2-ethylhexyl) phthalate, endometriosis, leiomyomata, mono-
benzyl phthalate, monobutyl phthalate, monoethyl phthalate, mono(2-ethyl-5-hydroxyhexyl) 
phthalate, mono(2-ethyl-5-oxohexyl) phthalate, mono(2-ethylhexyl) phthalate. Environ Health 
Perspect 118:825–832 (2010). doi:10.1289/ehp.0901543 [Online 25 February 2010]
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Wilcox et al. 1994) and are associated with 
significant costs for lost productivity and hos-
pitalization, accounting for several billion dol-
lars annually in the United States for health 
care alone (Flynn et al. 2006; Simoens et al. 
2007). Although the etiologies of both condi-
tions remain poorly understood, there is evi-
dence that they are influenced by endogenous 
sex steroid hormones (Eskenazi and Warner 
1997; Schwartz et al. 2000).
Four epidemiologic studies have assessed 
phthalate exposures in relation to these condi-
tions, and their findings suggest increased risk 
with higher levels of exposure to some phtha-
lates (Cobellis et al. 2003; Itoh et al. 2009; 
Luisi et al. 2006; Reddy et al. 2006). However, 
these studies were small (with 15–57 cases), 
adjusted for few if any potential confounders, 
and recruited controls from clinical settings, 
a potential source of bias. Moreover, most of 
these studies relied on plasma or serum levels 
of phthalate diesters and monoesters as bio-
markers of exposure. These exposure meas ures 
have two critical limitations. First, measure-
ments of diesters in any biologic medium 
are prone to contamination from phthalate-
containing laboratory supplies and other 
sources. Second, monoester measurements in 
blood are also susceptible to contamination, 
because serum enzymes can hydrolyze diesters 
in the blood to their respective monoesters 
after the specimen has been collected (Kato 
et al. 2003). The potential for contamination 
generally decreases when measuring phthalate 
monoester metabolites in urine. In assessing 
exposure to DEHP, the potential for contami-
nation is virtually eliminated when measuring 
the metabolites produced via enzymatic oxida-
tion (Kato et al. 2004).
Therefore, we examined the association of 
phthalate exposures with endometriosis and 
uterine leiomyomata, using cross-sectional data 
on urinary phthalate metabolite concentrations 
and self-reported reproductive history from 
1,227 women participating in the National 
Health and Nutrition Examination Survey 
(NHANES), 1999–2004. In addition, for 838 
women, we examined urinary concentrations 
of two oxidative metabolites of DEHP, which 
were measured in NHANES 2001–2004.
Materials and Methods
We used data from three cycles (1999–2000, 
2001–2002, 2003–2004) of NHANES 
[Centers for Disease Control and Prevention 
(CDC) 2009] to examine the association 
between urinary phthalate metabolites and 
previously diagnosed endometriosis or uterine 
leiomyomata. Briefly, NHANES is an ongo-
ing cross-sectional national survey conducted 
by the National Center for Health Statistics 
at the CDC, designed to collect data on the 
health and nutritional status of the civilian, 
noninstitutionalized U.S. population. Data 
estimates are sampling-probability based and 
are representative of the U.S. population. 
NHANES collects data through question-
naires, physical examinations, and laboratory 
tests. The assessment includes both a house-
hold interview and mobile examination com-
ponent (MEC), during which blood and urine 
are collected. Sociodemographic information 
and medical histories of the survey participants 
and their families were collected during the 
household interviews (CDC 2009). All par-
ticipants provided written informed consent, 
and the NCHS obtained institutional review 
board approval to conduct the survey.
Study population. NHANES 1999–2004 
was conducted in 87 locations throughout the 
United States and included examinations of 
31,126 people of all ages (15,942 females). A 
random one-third subset of participants was 
selected by NHANES for phthalate metabolite 
measurements, thereby retaining the represen-
tational aspect of these data (CDC 2009).
Women participating in the MEC assess-
ment and who completed the reproductive 
health questionnaire (given to all female par-
ticipants ≥ 12 years of age) were eligible for our 
analyses (n = 10,946). Questions pertaining to 
endometriosis and leiomyomata were restricted 
to women 20–54 years of age, further restrict-
ing the eligible population to 4,094 women. 
Of these women, 1,379 were included in the 
one-third subset of participants whose urinary 
specimens were analyzed for phthalates. We 
further excluded the 127 women whose uri-
nary creatinine concentrations were < 30 or 
> 300 mg/dL (Silva et al. 2004). An additional 
25 women were missing data on key covariates, 
leaving 1,227 women for our analyses of endo-
metriosis. Of these women, six were missing 
responses pertaining to uterine leiomyomata, 
and thus our analyses of this outcome included 
1,221 women. Because menopausal status is 
unlikely to influence the measurement of uri-
nary phthalate metabolites, we retained women 
who were postmenopausal at the time of the 
MEC interview. Our analyses of two oxidative 
metabolites of DEHP (assessed in NHANES 
2001–2004) in association with endometriosis 
and uterine leiomyomata, included 838 and 
835 women, respectively.
Women who were excluded from our 
main analyses did not differ substantially from 
included women with respect to a range of 
demographic, lifestyle, and reproductive health 
factors. For example, these groups were similar 
in age (35.6 vs. 35.7 years), age at menarche 
(12.6 vs. 12.6 years), parity status (25% vs. 
27% nulliparous), and race/ ethnicity (19% vs. 
21% African American).
Assessment of exposure to phthalates. We 
examined the metabolites of four prevalent 
phthalates measured in the three consecu-
tive NHANES cycles: MEHP, a monoester 
metabolite of DEHP; MBP; MEP, metabolite 
of diethyl phthalate (DEP); and mono benzyl 
phthalate (MBzP), the main metabolite of 
BzBP. In the 2001–2002 and 2003–2004 
cycles, concentrations of mono-n-butyl phtha-
late (MnBP) and mono-isobutyl phthalate were 
measured separately, and we summed these 
concentrations to obtain total MBP concen-
tration for these cycles. Data for other phtha-
late metabolites—monocyclohexyl phthalate, 
mono-n-octyl phthalate, and monoisononyl 
phthalate—were also available for the three 
NHANES cycles. However, these metabolites 
were detected in < 10% of the samples exam-
ined and were not included in our analyses.
Urinary concentrations of additional phtha-
late metabolites were introduced in the 2001–
2002 cycle. Of particular interest to our study 
were concentrations of two oxidative metabo-
lites of DEHP: mono(2-ethyl-5- hydroxyhexyl)
phthalate (MEHHP) and mono(2-ethyl-5-
 oxohexyl) phthalate (MEOHP). These metabo-
lites are produced only via enzymatic oxidation 
and are not produced in the environment. 
Moreover, their concentrations in urine are 
often at least an order of magnitude greater 
than concentrations of MEHP, making them 
potentially more sensitive measures of expo-
sure to DEHP. Therefore, we also examined 
these two oxidative metabolites for data in the 
2001–2002 and 2003–2004 cycles to evaluate 
the consistency of the findings for MEHP. As a 
summary measure of DEHP exposure, we com-
puted the molar sum concentration of MEHP, 
MEHHP, and MEOHP. In exploratory analy-
ses, we evaluated a fourth metabolite of DEHP, 
the oxidative metabolite, mono(2-ethyl-5-
 carboxypentyl) phthalate (MECPP), which was 
measured only in the 2003–2004 cycle.
Urine specimens for analyses, including 
phthalate metabolites and creatinine concen-
trations, were collected from each participant 
during one of three daily examination peri-
ods (0830–1200, 1230–1600, or 1630–2000 
hours) (Silva et al. 2004). After collection, 
urine specimens were aliquoted and stored 
cold (2–4°C) or frozen until they were shipped 
to the various laboratories for analysis (Silva 
et al. 2004). Urine specimens were analyzed 
for creatinine using a Beckman Synchron 
AS/ASTRA clinical analyzer (Beckman 
Instruments, Inc., Brea, CA) at the University 
of Minnesota Medical Center (Silva et al. 
2004). Samples collected for phthalate metab-
olite measurements were shipped on dry ice to 
the CDC’s National Center for Environmental 
Health. Urine samples were stored frozen at or 
below –20°C until analyzed. The samples were 
analyzed by solid-phase extraction followed by 
isotope-dilution high-performance liquid chro-
matography and tandem mass spectrometry as 
previously described (Blount et al. 2000a; Silva 
et al. 2003). To correct for urine dilution, we 
divided all phthalate metabolite concentrations 
by urinary creatinine concentration (Jackson 
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1966) and used the resulting creatinine-
 corrected concentrations for our primary 
analyses. Concentrations below the limit of 
detection (LOD) were replaced with the LOD 
divided by the square root of 2 (Hornung and 
Reed 1990). For any given urinary metabolite, 
the proportion of women in our study who 
had concentrations < LOD ranged from 0.2% 
to 20.5%.
Assessment of endometriosis and uterine 
leiomyomata. We classified each woman’s his-
tory of endometriosis and uterine leiomyomata 
according to her response to two questions: 
a) “Has a doctor or other health professional 
ever told you that you had endometriosis?” 
b) “Has a doctor or other health professional 
ever told you that you had uterine fibroids?” 
Women who answered positively to either of 
these questions were further queried regarding 
their age at first diagnosis (open-ended ques-
tion) (CDC 2009).
Assessment of covariates. Data on age at 
menarche, gravidity, parity, current pregnancy 
status, breast-feeding, use of hormonal contra-
ception, menopausal status, and gynecologic 
surgeries were obtained from the NHANES 
reproductive health questionnaire. We 
obtained data on age and race/ethnicity from 
the NHANES home interview.
Statistical analysis. We conducted all sta-
tistical analyses using SAS-callable SUDAAN, 
release 9.0.2 (RTI International, Research 
Triangle Park, NC). Unless specified, our 
analyses accounted for the complex sampling 
design of and nonresponse to the NHANES 
through use of sampling weights and sam-
ple design variables. Sampling errors were 
estimated using the Taylor series linearized 
method (CDC 2005).
We computed geometric mean phthalate 
metabolite concentrations within diagnosis 
groups, testing differences by case status using 
linear regression models of log-transformed 
phthalate concentrations. Within quartiles of 
each phthalate metabolite and within case sta-
tus for each of the two outcomes, we deter-
mined means and frequencies of various 
characteristics, testing differences using linear 
and logistic regression models. To evaluate the 
association between exposure to phthalates and 
the two outcomes, we used multiple logistic 
regression to derive adjusted odds ratios (ORs) 
and their 95% confidence intervals (CIs) across 
quartiles of each phthalate metabolite concen-
tration in relation to endometriosis and uterine 
leiomyomata. Tests for trend were calculated 
by including in the regression model a single 
variable coded as the median of each exposure 
quartile (Breslow and Day 1987). We con-
ducted separate analyses for each phthalate 
metabolite and for each outcome, comparing 
women who reported a history of the outcome 
with those who did not. Because endometriosis 
and uterine leiomyomata share some common 
hormonal characteristics, we also analyzed a 
combined end point defined as having a his-
tory of one or both conditions, allowing for 
increased statistical power, the caveat being that 
associations could be diluted if the phthalate-
related etiologies differ by outcome. Because 
the distributions of the urinary phthalate con-
centrations were strongly right-skewed, we also 
conducted analyses in which we compared 
women in the highest quartile of each metabo-
lite with those in the lowest three quartiles.
As potential confounders, we examined 
variables that were associated with urinary 
phthalate concentrations in our study popula-
tion and are also considered well-established 
risk factors for the outcomes of interest. Final 
models were adjusted for age (years) at time 
of NHANES urine sample collection, race/ 
ethnicity (African American, white, other), age 
at menarche (years), and both current preg-
nancy and breast-feeding status. Because of the 
possibility that hysterectomy, nulliparity, and 
oral contraceptive use could be consequences of 
the outcomes, we did not adjust for these vari-
ables. For models involving only 2001–2004 
data, we did not adjust for breast-feeding sta-
tus, because very few women in this popula-
tion (n = 28) reported breast-feeding. We were 
unable to consider infertility history, because 
these data were not publicly available.
The exposure interval directly reflected 
by urinary phthalate concentrations is quite 
short. To evaluate the associations between 
phthalate exposures and the two outcomes in 
a manner that better reflected the exposures 
that were actually measured, we conducted 
secondary analyses that excluded women who 
had the diagnosis of interest or a hysterectomy 
> 10 years before their NHANES evaluation 
[leaving n = 1,146 (47 cases) and 1,134 (96 
cases) for analyses of endometriosis and uter-
ine leiomyomata, respectively] and > 7 years 
before [leaving n = 1,128 (38 cases) and 1,112 
(79 cases) for endometriosis and leiomyomata, 
respectively]. For the analyses of uterine leio-
myomata and the combined end point, we had 
sufficient cases to additionally make these exclu-
sions on the basis of a 5-year interval [leaving 
n = 1,096 (67 cases) for leiomyomata analyses].
We performed several sensitivity analyses. 
In parallel to our primary analyses of creati-
nine-corrected urinary phthalate metabolite 
concentrations, we conducted analyses using 
raw phthalate metabolite concentrations as 
the measures of exposure and then included 
urinary creatinine as an additional term in the 
logistic regression models. We also reanalyzed 
the data, allowing for the inclusion of the 
127 women with very low (< 30 mg/dL) or 
very high (> 300 mg/dL) urinary creatinine 
concentrations. Finally, although our analy-
ses of MEHHP and MEOHP constitute a 
sensitivity analysis of the MEHP analyses, for 
enhanced comparability, we evaluated MEHP 
over the same period in which the oxidative 
metabolites were assessed (2001–2004).
We considered a p-value < 0.05 to be statis-
tically significant. For all analyses, we used cre-
atinine-corrected urinary concentrations of the 
phthalate metabolites, unless stated otherwise.
Results
Among the 1,227 women included in our 
analysis, the unweighted percentages of those 
20–29, 30–39, 40–49, and 50–54 years of age 
were, respectively, 33.8%, 27.1%, 27.8% and 
11.3%. Eighty-seven women (7%) reported 
a previous diagnosis of endometriosis, 151 
(12%) reported a previous diagnosis of uterine 
leiomyomata, and 201 (16%) reported a pre-
vious diagnosis of either condition [34 (3%) 
had both conditions]. Women with a history 
of endometriosis reported that their diagno-
ses occurred < 1 year to 34 years before their 
NHANES evaluation (median, 9 years). For 
uterine leiomyomata, this range was < 1 to 
36 years (median, 7 years).
Table 1 lists the geometric mean urinary 
concentrations of the phthalate metabo-
lites. Urinary concentrations of MBP were 
somewhat higher among women with endo-
metriosis, and women with endometriosis or 
leiomyomata had significantly lower concen-
trations of MEHP than did women without 
these conditions (p = 0.03).
Women in the highest quartiles of urinary 
MEP were significantly more likely to be non-
Hispanic black or Mexican American than 
were women in the lowest quartiles (Table 2). 
Women in the lowest MEP quartile were more 
likely to be currently breast-feeding than were 
women in the higher quartiles. Women in the 
highest quartile of urinary MBzP were sig-
nificantly younger, less likely to be Mexican-
American, and more likely to be pregnant than 
were women in the lower quartiles. None of the 
characteristics varied significantly across quartiles 
of urinary MEHP, but some patterns emerged 
in data on the DEHP oxidative metabo lites 
(data not shown). For example, compared with 
the lowest quartiles of urinary MEOHP, women 
in the highest quartile were more likely to be 
non-Hispanic white (p = 0.02).
Women who reported a history of endo-
metriosis were significantly older, more likely 
to be non-Hispanic white, and less likely to 
be non-Hispanic black or Mexican American 
than were noncases (Table 2). They were also 
significantly less likely to have been currently 
breast-feeding. Women who reported a his-
tory of uterine leiomyomata were also signifi-
cantly older than noncases, but in contrast to 
the race/ethnicity pattern for endometriosis, 
leiomyomata cases were significantly more 
likely than noncases to be non-Hispanic black. 
Nulliparity and current use of oral contracep-
tives were significantly less common among 
leiomyomata cases than among noncases. 
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History of hysterectomy was common among 
women who reported either condition.
Urinary concentration of MBP was weakly 
associated with increased odds of both endo-
metriosis (highest vs. lowest three quartiles: 
OR = 1.36; 95% CI, 0.77–2.41) and leio-
myomata (highest vs. lowest three quartiles: 
OR = 1.56; 95% CI, 0.93–2.61) (Table 3). 
When we examined the outcomes as a com-
bined end point, the OR comparing the 
highest versus lowest three quartiles of uri-
nary MBP was 1.71 (95% CI, 1.07–2.75). 
Urinary concentration of MEHP was inversely 
associated with both endometriosis (highest 
vs. lowest three quartiles: OR = 0.44; 95% 
CI, 0.19–1.02) and leiomyomata (highest vs. 
lowest three quartiles: OR = 0.63; 95% CI, 
0.35–1.12). For endometriosis, ORs decreased 
significantly with progressively higher levels of 
MEHP (ptrend = 0.05). For the outcomes com-
bined, we found statistically significant inverse 
associations corresponding to both the contrast 
between highest and lowest three quartiles of 
MEHP (OR = 0.59; 95% CI, 0.37–0.95) and 
the trend across increasing quartiles of MEHP 
(ptrend = 0.03).
The associations of urinary MBP and 
MEHP concentrations with these outcomes 
either remained unchanged or became stron-
ger when we excluded women whose diagno-
ses or hysterectomy occurred further in the 
past. For MBP and leiomyomata, when we 
excluded women whose leiomyomata diagnosis 
or hysterectomy occurred > 7 years before their 
NHANES examination, the OR for women 
in the highest quartile of MBP concentra-
tion versus those in the lowest three quartiles 
increased to 1.86 (95% CI, 0.94–3.68). The 
corresponding OR for the combined out-
come increased to 2.16 (95% CI, 1.23–3.77), 
with similar findings with exclusions based on 
a 5-year interval from diagnosis. For MEHP 
and endometriosis, when we excluded women 
whose diagnosis or hysterectomy occurred 
> 7 years before their NHANES examination, 
the OR for women in the highest quartile of 
MEHP concentration versus those in the low-
est three quartiles decreased to 0.19 (95% CI, 
0.05–0.78). For analyses of MEHP and the 
combined outcome, when we made exclusions 
based on a 5-year interval, the findings were 
consistent with those from our main analyses.
In analyses of the oxidative metabolites of 
DEHP (MEHHP and MEOHP), we found 
associations that were consistent with that 
between MEHP and endometriosis, but not 
with that between MEHP and leiomyomata 
(Table 4). Specifically, the OR of endometriosis 
for women in the highest quartile of MEHHP 
concentration versus those in the lowest three 
quartiles was 0.46 (95% CI, 0.18–1.21), and 
the comparable ORs for MEOHP and the 
molar sum of MEHP, MEHHP, and MEOHP 
also indicated an inverse association. In contrast, 
concentrations of the oxidative metabolites and 
the molar sum were not consistently associated 
with leiomyomata. Results for the highest versus 
the lowest three quartiles of MECPP, measured 
only in 2003–2004, were largely consistent with 
Table 1. Geometric mean urinary creatinine and creatinine-corrected urinary concentration of phthalate metabolites, by diagnosis.a
Geometric mean (SE)
All women 
(n = 1,227)
Women with 
endometriosis 
(n = 87)
Women with 
uterine leiomyomata 
(n = 151)
Women with 
neither condition 
(n = 1,020)
Percentage of all 
women with levels 
< LODb
Urinary creatinine (mg/dL) 108.2 (2.5) 108.4 (6.3) 114.0 (5.6) 107.3 (3.0) 0.0
Phthalate metabolites (ng/mg)
MBP 26.2 (0.9) 28.9 (4.1) 27.1 (2.6) 25.5 (1.0) 0.5
MEP 216.2 (11.9) 207.0 (27.5) 210.2 (21.9) 219.9 (14.1) 0.2
MEHP 3.3 (0.1) 2.5 (0.4) 2.8 (0.3) 3.4 (0.1)* 20.5
MBzP 14.1 (0.6) 14.4 (2.5) 13.6 (1.2) 14.1 (0.6) 0.6
Oxidative metabolites of DEHP (ng/mg) (2001–2004)c
MEHHP 19.4 (1.2) 16.5 (2.8) 20.0 (2.0) 19.7 (1.4) 0.8
MEOHP 13.3 (0.8) 11.5 (1.9) 13.8 (1.4) 13.5 (1.0) 1.7
aNumbers of women with and without a diagnosis do not sum to the total (1,227) because 34 women have both diagnoses, and data on diagnosis of uterine leiomyomata are missing 
for three women. bPercentages for MEHHP and MEOHP are based on the 2001–2004 sample population (n = 838). cn = 838, 57, 113, and 689 for all women, women with endometriosis, 
women with uterine leiomyomata, and women with neither condition, respectively. *Significantly higher (p = 0.03) than among women with endometriosis or uterine leiomyomata.
Table 2. Characteristics of the study population, by quartile of creatinine-corrected urinary phthalate concentration and by diagnosis status.
Race/ethnicity (%) Gynecologic and reproductive history (%)
Quartile
Range 
(ng/mg)
Mean 
age
Non-
Hispanic 
black
Non-
Hispanic 
white
Mexican 
American
Other/ 
mixed Nulliparous
Currently 
pregnant
Currently 
breast-
feeding
Age at menarche (years) Currently  
uses oral  
contraceptives
History of 
hysterectomy< 12 12–13 > 13
MBP Lowest 0.4–15.6 37.5 10.9 72.3 8.1 8.7 25.5 4.5 4.7 24.7 51.3 24.0 14.5 10.7
Second 15.7–25.3 36.1 13.2 72.1 8.6 6.1 30.0 8.0 1.8 23.1 54.0 22.9 14.4 11.8
Third 25.4–41.3 37.5 11.7 64.0 8.1 16.2 26.6 4.9 2.0 23.2 54.3 22.5 12.6 10.6
Highest 41.4–6,429 37.8 13.9 63.2 7.6 15.3 29.1 6.2 2.3 22.2 57.1 20.8 10.9 13.7
MEP Lowest 0.6–100 37.6 8.8 73.4 4.7 13.1 28.0 5.6 5.6 24.0 58.4 17.6 11.7 11.2
Second 101–209 36.9 11.8 72.3 6.3 9.6 27.0 4.9 2.3 27.0 50.4 22.7 13.1 12.3
Third 210–517 37.3 14.0 62.9 10.8 12.3 26.4 6.4 0.9 22.3 51.1 26.6 12.3 14.7
Highest 518–29,986 37.2 15.8* 61.1* 11.2* 11.8 29.9 6.8 1.7* 19.1 57.0 23.9 15.4 8.4
MEHP Lowest 0.2–1.4 38.3 9.7 69.2 9.0 12.1 29.8 5.1 2.9 26.1 54.3 19.6 9.7 11.0
Second 1.5–3.2 37.3 13.2 63.6 7.8 15.3 25.0 7.4 4.0 25.2 47.8 26.9 11.5 10.5
Third 3.3–6.3 36.8 11.5 67.9 9.2 11.4 26.3 3.9 0.9 20.3 58.9 20.8 19.2 14.0
Highest 6.4–538 36.4 15.4 70.8 6.3 7.4 29.9 7.0 2.7 21.1 56.4 22.5 12.5 11.5
MBzP Lowest 0.2–7.7 38.9 12.9 67.4 10.5 9.3 32.2 4.7 2.1 22.7 52.1 25.2 14.6 10.5
Second 7.8–13.1 37.4 12.1 65.2 8.8 10.9 28.7 3.6 2.6 24.7 53.2 22.1 15.4 9.7
Third 13.2–23.2 36.9 12.1 67.5 4.5 12.9 26.1 5.6 2.4 20.4 57.6 22.0 11.6 14.4
Highest 23.3–650 35.9* 12.6 71.1 5.8* 10.5 24.5 9.5* 3.6 25.5 53.5 21.0 10.9 12.1
Endometriosis Yes 40.4 5.3 83.7 3.0 8.0 24.8 2.9 0.1 26.1 55.8 18.1 10.4 49.3
No 36.9* 13.2* 66.2* 8.6* 12.0 28.1 6.2 3.0* 23.0 54.0 23.0 13.4 7.8*
Uterine Yes 44.3 18.9 67.1 3.4 10.5 16.6 2.8 1.6 27.1 52.8 20.0 6.5 42.3
leiomyomata No 36.0* 11.4* 67.9 8.1* 11.8 29.8* 6.4 2.9 22.8 54.4 22.8 14.2* 6.4*
*Difference across the quartiles or by diagnosis, p < 0.05. 
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the pattern of these findings, with OR = 0.49 
(95% CI, 0.12–1.93) for endometriosis (57 
cases) and OR = 1.63 (95% CI, 0.89–2.96) for 
uterine leiomyomata (113 cases).
Urinary concentrations of MEP and MBzP 
were not appreciably associated with risk of 
endometriosis or leiomyomata. Because cur-
rent pregnancy was more common with higher 
urinary MBzP and less common in both out-
comes, we repeated analyses of MBzP excluding 
pregnant women, but the results were similar.
Moreover, our results overall did not 
change after further adjustment for parity or 
use of oral contraceptives or when we excluded 
women who used oral contraceptives. They also 
did not change substantially when we replaced 
the creatinine-corrected urinary phthalate con-
centrations with uncorrected concentrations 
or when we included women with extreme 
 urinary creatinine concentrations.
Discussion
In this large nationally representative cross-
sectional study, in which we used urinary 
phthalate metabolite concentrations as bio-
markers of exposure to four parent phthalates, 
we observed weak positive associations for uri-
nary MBP, and weak inverse associations for 
urinary MEHP, in relation to self-reported 
history of endometriosis and leiomyomata. 
Our analyses of the two oxidative metabolites 
of DEHP—MEHHP and MEOHP—yielded 
findings that were consistent with our findings 
for MEHP with respect to endometriosis, but 
not with respect to uterine leiomyomata. We 
found little evidence for associations of urinary 
MEP and MBzP with each of these outcomes.
Our results for MEHP and endometriosis 
do not agree with findings from the three case–
control studies on this subject, all which identi-
fied positive associations between markers of 
DEHP exposure and risk of endometriosis. 
Cobellis et al. (2003) reported higher plasma 
DEHP concentrations [median, 0.57 µg/mL; 
interquartile range (IQR), 0.06–1.23] among 
women with endometriosis than among con-
trols (0.18 µg/mL; IQR, 0–0.44; p = 0.005). 
However, plasma MEHP concentrations were 
generally low and did not differ between the 
outcome groups: for cases the median MEHP 
was 0.38 µg/mL (IQR, 0.1–0.97), and for 
controls the median was 0.58 µg/mL (IQR, 
0.34–0.71). Our MEHP results also diverge 
from a subsequent case–control study by 
Reddy et al. (2006), in which women with 
laparoscopy- confirmed endometriosis had 
significantly higher plasma concentrations of 
DEHP compared with controls, and concen-
trations appeared more elevated with increas-
ingly severe stage of endometriosis. In a third 
case– control study by Itoh et al. (2009), 
Table 3. Adjusteda ORs of endometriosis or uterine leiomyomata by concentration of creatinine-corrected urinary phthalate metabolite, in quartiles (1999–2004).
MBP MEP MEHP MBzP
Cases/n OR (95% CI) Cases/n OR (95% CI) Cases/n OR (95% CI) Cases/n OR (95% CI)
Endometriosis 
Lowest Q 22/303 1.00 Reference 28/304 1.00 Reference 28/309 1.00 Reference 23/306 1.00 Reference
Second Q 20/306 0.75 (0.38–1.47) 20/309 0.89 (0.44–1.82) 21/303 0.78 (0.38–1.58) 19/306 0.84 (0.37–1.89)
Third Q 22/310 0.96 (0.49–1.91) 18/304 1.13 (0.56–2.27) 23/309 0.89 (0.42–1.90) 23/309 1.17 (0.47–2.94)
Highest Q 23/308 1.24 (0.65–2.34) 21/310 1.12 (0.53–2.35) 15/306 0.39 (0.16–0.95) 22/306 1.17 (0.42–3.27)
ptrend = 0.3 ptrend = 0.6 ptrend = 0.05 ptrend = 0.6
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest vs. lowest three Qs 23/308 64/919 1.36 (0.77–2.41) 21/310 66/917 1.12 (0.58–2.17) 15/306 72/921 0.44 (0.19–1.02) 22/306 65/921 1.16 (0.58–2.33)
Excluding women who had 
diagnosis or hysterectomy
> 10 years ago 11/289 36/857 1.47 (0.70–3.10) 10/290 37/856 0.87 (0.30–2.51) 5/284 42/862 0.21 (0.06–0.74) 13/292 34/854 1.55 (0.55–4.37)
> 7 years ago 9/284 29/844 1.45 (0.64–3.28) 7/285 31/843 0.80 (0.23–2.76) 4/282 34/846 0.19 (0.05–0.78) 8/286 30/842 0.94 (0.28–3.12)
Uterine leiomyomata
Lowest Q 33/301 1.00 Reference 41/301 1.00 Reference 43/307 1.00 Reference 37/306 1.00 Reference
Second Q 29/305 0.66 (0.40–1.10) 31/309 0.72 (0.35–1.46) 37/301 1.03 (0.59–1.80) 36/302 1.11 (0.59–2.07)
Third Q 39/308 0.76 (0.46–1.28) 45/303 1.29 (0.74–2.25) 42/307 1.13 (0.65–1.95) 47/309 1.16 (0.64–2.13)
Highest Q 50/307 1.26 (0.70–2.27) 34/308 0.85 (0.47–1.54) 29/306 0.66 (0.35–1.26) 31/304 1.14 (0.54–2.39)
ptrend = 0.2 ptrend = 0.9 ptrend = 0.2 ptrend = 0.8
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest vs. lowest three Qs 50/307 101/914 1.56 (0.93–2.61) 34/308 117/913 0.86 (0.51–1.46) 29/306 122/915 0.63 (0.35–1.12) 31/304 120/917 1.04 (0.57–1.92)
Excluding women who had 
diagnosis or hysterectomy
> 10 years ago 30/281 66/853 1.61 (0.86–3.01) 25/291 71/843 1.10 (0.60–2.01) 17/284 79/850 0.60 (0.30–1.23) 22/291 74/843 0.97 (0.45–2.08)
> 7 years ago 26/274 53/838 1.86 (0.94–3.68) 20/285 59/827 1.14 (0.58–2.26) 14/281 65/831 0.57 (0.26–1.29) 21/288 58/824 1.22 (0.55–2.74)
> 5 years ago 23/269 44/827 1.87 (0.96–3.65) 19/283 48/813 1.35 (0.68–2.68) 12/278 55/818 0.60 (0.27–1.36) 19/284 48/812 1.33 (0.59–3.00)
Endometriosis or uterine leiomyomata
Lowest Q 42/301 1.00 Reference 59/301 1.00 Reference 60/307 1.00 Reference 48/306 1.00 Reference
Second Q 41/305 0.74 (0.46–1.20) 44/309 0.75 (0.45–1.24) 50/301 0.93 (0.56–1.54) 47/302 1.01 (0.55–1.83)
Third Q 53/308 0.97 (0.62–1.53) 55/303 1.15 (0.75–1.78) 52/307 0.94 (0.57–1.55) 61/309 1.25 (0.70–2.24)
Highest Q 65/307 1.55 (0.87–2.75) 43/308 0.80 (0.49–1.30) 39/306 0.57 (0.33–0.98) 45/304 1.27 (0.59–2.72)
ptrend = 0.03 ptrend = 0.6 ptrend = 0.03 ptrend = 0.5
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest 
Q
Lowest 
three Qs OR (95% CI)
Highest vs. lowest three Qs 65/307 136/914 1.71 (1.07–2.75) 43/308 158/913 0.83 (0.51–1.37) 39/306 162/915 0.59 (0.37–0.95) 45/304 156/917 1.16 (0.66–2.05)
Excluding women who had 
diagnosis or hysterectomy
> 10 years ago 38/275 80/835 2.04 (1.12–3.45) 27/286 91/824 0.88 (0.50–1.54) 20/278 98/832 0.54 (0.28–1.02) 29/284 89/826 1.25 (0.62–2.52)
> 7 years ago 32/268 66/819 2.16 (1.23–3.77) 21/279 77/808 0.91 (0.48–1.72) 16/274 82/823 0.50 (0.24–1.02) 24/278 74/809 1.19 (0.60–2.34)
> 5 years ago 27/262 54/806 2.08 (1.14–3.80) 18/275 63/793 0.95 (0.50–1.80) 14/272 67/796 0.53 (0.25–1.13) 22/275 59/793 1.38 (0.66–2.87)
Q, quartile. 
aAdjusted for age, race/ethnicity, age at menarche, current pregnancy status, and current breast-feeding status.
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laparoscopy-confirmed cases were more likely 
than controls to have “elevated” creatinine-cor-
rected urinary MEHP concentrations [above 
the controls’ median (4.2 ng/mg)], although 
this association was not significant. Findings 
were weaker for urinary MEHHP, MEOHP, 
and the molar sum of the three DEHP metab-
olites. Itoh et al. also found significantly higher 
uncorrected concentrations of all three DEHP 
metabolites with increasingly severe stage of 
endometriosis (p < 0.02), but these trends 
diminished upon creatinine correction. The 
discrepant findings may stem from differences 
in exposure assessment and/or case definition. 
For measures of exposure to DEHP, the first 
two case–control studies used blood-based 
concentrations of DEHP, which is no longer 
considered a valid approach for assessing expo-
sure because of concerns about contamination 
from laboratory equipment and other external 
sources. The correlation between serum DEHP 
and MEHP concentrations was weak in the 
Cobellis et al. (2003) study (r = 0.16, p ≥ 0.3), 
raising questions about the utility of the serum 
DEHP measurements, including the possibility 
that DEHP measurements were affected by 
external contamination (Hauser and Calafat 
2005). Blood-based concentrations of MEHP 
are also prone to contamination from DEHP 
that is also present in the specimen, because 
serum enzymes can hydrolyze DEHP to 
MEHP during storage (Kato et al. 2003). For 
their case definitions, all three case–control 
studies enrolled women with laparoscopically 
confirmed endometriosis. Cases in the Cobellis 
et al. (2003) study underwent further histologic 
confirmation. However, because all participants 
were enrolled in clinical settings, it is possible 
that DEHP and MEHP concentrations were 
affected by supplies used in very recent medical 
procedures associated with the clinical condi-
tions (Hauser and Calafat 2005). For example, 
at least some of the specimens in the Cobellis 
et al. (2003) study were collected immediately 
before anesthesia for laparoscopy, when the 
women were likely on an intravenous therapy 
line, a potential source of DEHP exposure 
(U.S. Food and Drug Administration 2002). 
This may explain why plasma MEHP concen-
trations in the Cobellis et al. (2003) study were 
about 100 times the urinary MEHP concentra-
tions among the women in our study. It is also 
possible that controls recruited from a clinical 
setting—such as those seeking treatment for 
infertility in the Itoh et al. (2009) study—had 
conditions that were themselves influenced by 
exposure to phthalates, leading to biased find-
ings (Hernán et al. 2004).
In contrast, our results for MBP agree with 
results from the Reddy et al. (2006) study in 
which women with endometriosis had signifi-
cantly higher plasma concentrations of DBP 
(the parent compound of MBP) compared 
with controls (Reddy et al. 2006). Nonetheless, 
blood measures of DBP entail limitations as 
described for DEHP, and even in the absence 
of external contamination, there remains the 
possibility that some of the DBP could be 
missed because of its hydrolysis to MBP (Kato 
et al. 2003). In the study by Itoh et al. (2009), 
endometriosis was not significantly associated 
with having an “elevated” creatinine-corrected 
urinary MnBP concentration (above the 
median among the controls, 43.4 ng/mg), and 
there was no apparent trend in urinary MnBP 
across severity classes of the condition.
Our null findings for MBzP and endo-
metriosis were consistent with those of Itoh 
et al. (2009) but diverged from those of Reddy 
et al. (2006) in which plasma BzBP concentra-
tions among cases were significantly higher 
than those among controls. Similar to our find-
ings for MEP, Itoh et al. (2009) did not find 
a significant association between creatinine-
 corrected urinary MEP and endometriosis.
Our weakly inverse association between 
MEHP and leiomyomata agrees with the 
case–control study by Luisi et al. (2006), in 
which significantly lower serum DEHP and 
MEHP concentrations were found among 
 hysterectomy-confirmed cases of leiomyomata 
relative to controls (confirmed by ultrasound 
to be free of disease). The measurement con-
cerns we described above also pertain to this 
case–control study, but they would likely serve 
to over estimate DEHP exposures among the 
cases, rendering the estimates from this case–
control study conservative. However, this 
study may have reduced external contamina-
tion through its use of glass collection and 
storage materials.
Our results are also consistent with animal 
data showing positive associations of exposure 
to DEHP and its metabolite MEHP with ano-
vulation or delayed ovulation, longer estrous 
cycles, decreased synthesis of estradiol, and 
decreased serum progesterone levels (Davis 
et al. 1994a, 1994b; Lovekamp and Davis 
2001), all of which would predict a protective 
effect on uterine leiomyomata and endometri-
osis. The pathophysiology of leiomyomata is 
believed to depend on the biological activ-
ity of the endogenous sex steroid hormones 
estrogen (estradiol, estrone, estriol) and pro-
gesterone (Rein 2000; Rein and Nowak 1992; 
Rein et al. 1995), as well as locally derived 
growth factors (Andersen 1998). The hor-
mone-dependent nature of leiomyomata is 
supported by the following observations: They 
do not occur before menarche, they have an 
increased concentration of estrogen and pro-
gesterone receptors compared with normal 
myometrium (Strauss and Coutifaris 1999), 
and they shrink in volume after menopause 
or with suppression of ovarian function via 
gonadotropin-releasing hormone (GnRH) 
agonist therapy or oophorectomy (Friedman 
et al. 1990). The literature on the relation of 
endogenous sex hormones to leiomyomata 
is limited and mixed. Although an earlier 
study reported than serum estrogen levels did 
not differ significantly between leiomyomata 
cases and controls (Potgieter et al. 1995), a 
subsequent study reported that urinary con-
centrations of many sex hormones, including 
17β-estradiol, were significantly higher among 
leiomyomata cases than controls (Jung et al. 
2004). Several epidemiologic studies show an 
increased risk of leiomyomata associated with 
reproductive and hormonal factors, including 
early age at menarche and nulliparity, which 
Table 4. Adjusteda ORs of endometriosis or uterine leiomyomata by concentration of creatinine-corrected urinary phthalate metabolites of DEHP (2001–2004).
MEHP MEHHP MEOHP
Molar sum of  
MEHP, MEHHP, and MEOHP
Cases/n OR 95% CI Cases/n OR 95% CI Cases/n OR 95% CI Cases/n OR 95% CI
Endometriosis (n = 838)
Lowest three quartilesb 45/615 1.00 Reference 47/628 1.00 Reference 46/627 1.00 Reference 47/629 1.00 Reference
Highest quartileb 12/223 0.60 (0.24–1.50) 10/210 0.46 (0.18–1.21) 11/211 0.62 (0.27–1.44) 10/209 0.48 (0.18–1.25)
Uterine leiomyomata (n = 835)
Lowest three quartilesb 91/612 1.00 Reference 87/626 1.00 Reference 84/625 1.00 Reference 86/627 1.00 Reference
Highest quartileb 22/223 0.66 (0.32–1.37) 26/209 0.97 (0.55–1.71) 29/210 1.43 (0.87–2.37) 27/208 1.08 (0.60–1.95)
Endometriosis or uterine leiomyomata (n = 835)
Lowest three quartilesb 115/612 1.00 Reference 116/626 1.00 Reference 113/625 1.00 Reference 115/627 1.00 Reference
Highest quartileb 31/223 0.69 (0.38–1.25) 30/209 0.69 (0.43–1.12) 33/210 0.96 (0.63–1.47) 31/208 0.77 (0.46–1.29)
aAdjusted for age, race/ethnicity, age at menarche, and current pregnancy status. Further adjustment for current breast-feeding status created model instability. bRanges for MEHP 
groups (ng/mg): 0.2–6.3 (lowest three quartiles) and 6.4–538 (highest quartile); ranges for MEHHP groups (ng/mg): 0.5–31.9 (lowest three quartiles) and 32.0–1885 (highest quartile); ranges 
for MEOHP groups (ng/mg): 0.6–21.3 (lowest three quartiles) and 21.4–1115 (highest quartile); and ranges for molar sum of MEHP, MEHHP, and MEOHP (nmol/mg): 0.6–27.5 (lowest three 
quartiles) and 27.5–1094 (highest quartile).
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suggests that increased menstrual cycling is a 
risk factor (Schwartz 2001; Wise et al. 2004).
Similarly, endometriosis is associated 
with abnormal steroid production and activ-
ity (Dizerega et al. 1980; Eskenazi and 
Warner 1997), with diagnoses occurring 
post menarchally (Houston 1984) and symp-
toms abating after menopause. Endometriotic 
implants are dependent on estrogen for their 
maintenance and growth (Dizerega et al. 
1980; Gurates and Bulun 2003), and reduc-
tion of estradiol production, via either surgi-
cal (oophorectomy) or hormonal (GnRH 
agonist analogues) intervention, causes atro-
phy of endometriosis lesions and is effective in 
treating pain symptoms. High-dose synthetic 
progestins are effective in the treatment of 
endometriosis through suppression of luteiniz-
ing hormone and FSH secretion that inhib-
its estradiol production, direct antiestrogenic 
effects on the lesions, and induction of pseudo-
decidualization (Taylor and Lebovic 2009). 
Estradiol production is up-regulated in endo-
metriotic implants, whereas estradiol metabo-
lism is impaired because of a deficiency of the 
enzyme 17β-hydroxysteroid dehydrogenase 
type 2 (Gurates and Bulun 2003). Also, the 
progesterone receptor subtype B is deficient in 
endometriosis tissue (Attia et al. 2000). In epi-
demiologic studies, endometriosis is positively 
associated with early age at menarche, shorter 
cycle length, decreased parity, and not breast-
feeding (Missmer et al. 2004a), all of which can 
affect menstrual cycling and lifetime cumulative 
exposure to estrogens.
Nonetheless, although our findings for 
DEHP’s oxidative metabolites provided sup-
port for an inverse association between DEHP 
exposure and endometriosis, they raised doubts 
about an association with leiomyomata. In the 
subset of women evaluated in 2001–2004, we 
compared findings for urinary concentrations 
of MEHHP and MEOHP with findings for 
MEHP, and both MEHHP and MEOHP 
were detectable in nearly all specimens in our 
study, including those in which MEHP was 
undetectable. The associations of the two oxi-
dative metabolite concentrations with endo-
metriosis were inverse and remarkably similar 
in magnitude to the corresponding association 
for MEHP. However, the associations between 
the oxidative metabolites and uterine leio-
myomata were not consistent with the inverse 
(albeit nonsignificant) corresponding associa-
tion for MEHP. The association for MEHHP 
was essentially null [OR = 0.97 (95% CI, 0.55–
0.71) for women in the highest quartile vs. the 
lowest three quartiles], and although the asso-
ciations for MEOHP and MECPP suggested 
a positive (nonsignificant) association, further 
analyses at alternative threshold concentrations 
were more consistent with null associations 
[e.g., OR = 0.92 (95% CI, 0.39–2.15) compar-
ing highest sextile of urinary MEOHP vs. the 
lowest five]. Although these findings emanated 
from a subset of participants, they suggest that 
the inverse association between MEHP and 
leiomyomata may be a chance finding.
Our study has three principal limitations 
that warrant consideration. First, with its cross-
sectional design, the assessment of exposure 
to phthalates may have occurred several years 
after diagnosis of the outcomes. It is uncertain 
whether diagnosis would directly influence uri-
nary phthalate concentrations by altering the 
metabolism of phthalates, although recent data 
from 60 women in the Early Pregnancy Study 
indicate little variation in urinary phthalate 
metabolite concentrations across phases of the 
menstrual cycle (Baird et al. 2009), suggesting 
that changes in a woman’s endogenous hor-
monal milieu (which might occur with age, oral 
contraceptive use, or hysterectomy) have mini-
mal effects on phthalate metabolism. However, 
it remains possible that diagnoses could indi-
rectly affect urinary phthalate concentrations via 
exposures resulting from diagnosis, as described 
above. However, given the short half-lives of 
the metabolites, it seems unlikely that diagnosis-
related procedures occurring more than a few 
days before the NHANES examination would 
be an important source of exposure. Moreover, 
although medications have recently been identi-
fied as an important source of DBP and DEP 
exposures (Hauser et al. 2004; Hernández-
Díaz et al. 2009), medications typically indi-
cated for endometriosis and leiomyomata are 
not likely to contain these compounds because 
they are not coated for timed release. Even in 
the absence of reverse causation, the increas-
ing interval between the relevant and measured 
exposures is a form of measurement error—
nondifferential with respect to exposure or dis-
ease status—that could attenuate the observed 
associations. The associations between MBP 
and uterine leiomyomata and between MEHP 
and endometriosis became stronger when we 
confined analyses to women whose diagnoses 
or hysterectomies occurred within 7 years of 
their NHANES evaluation, suggesting that this 
type of exposure measurement error may have 
affected our results.
Our exposure measure is limited in that 
phthalates do not bioaccumulate and have 
short half-lives in the body. Therefore, measure-
ments taken at a single point in time are less 
reliable indicators of typical exposures than, for 
example, a series of measurements taken over 
several weeks. Yet emerging data suggest some 
consistency of phthalate exposures over time 
among reproductive-age women. In their study 
of 46 women 35–49 years of age who provided 
first-morning urinary voids on 2 consecutive 
days, Hoppin et al. (2002) found intraclass 
correlations (ICCs) ranging from 0.53 to 0.80 
for creatinine-corrected urinary concentrations 
of MBP, MEP, MEHP, and MBzP. Over lon-
ger time intervals, these correlations may be 
weaker, as suggested by data from two studies: 
the Early Pregnancy Study, which reported 
ICCs for these urinary metabolites ranging 
from 0.36 to 0.53 for measurements taken 
over 2-week intervals (Baird et al. 2009); and 
a study of 28 pregnant women (Adibi et al. 
2008), which reported ICCs for the creatinine-
corrected urinary phthalate concentrations 
ranging from 0.21 to 0.65 for measurements 
taken repeatedly over 6 weeks. Therefore, it 
is possible that we have underestimated the 
true associations, where they exist, between 
phthalate exposures and endometriosis and 
uterine leiomyomata. Nonetheless, our expo-
sure measures do represent an advance over 
measures used in previous work in that we have 
used urinary measures of phthalate metabolites, 
which are far less vulnerable to contamination 
than phthalate diester measurements in blood. 
Moreover, we have evaluated exposures to four 
phthalates, conferring a degree of specificity to 
our findings.
Finally, an important limitation of our 
study is that measures of both outcomes were 
based solely on self-report of physician diag-
nosis. Prevalence estimates of these conditions 
in our study population are similar to stud-
ies based on hospital-discharge and prospec-
tive cohort data (Eskenazi and Warner 1997; 
Missmer and Cramer 2003; Schwartz and 
Marshall 2000; Wise et al. 2005). Two large 
prospective studies of self-reported leiomyo-
mata that validated the reports against medical 
records indicated a low proportion of false pos-
itives (Marshall et al. 1997; Wise et al. 2004); 
therefore, specificity of diagnosis is likely to 
be high. False reports of endometriosis diag-
nosis may occur more frequently (Missmer 
et al. 2004b), but the proportion of undiag-
nosed endometriosis cases is likely to be smaller 
(Zondervan et al. 2002). For both outcomes, it 
seems unlikely that misclassification of disease 
status was influenced by degree of phthalate 
exposure, and such nondifferential misclas-
sification would have attenuated our findings. 
Our findings for endometriosis may have been 
further influenced by phthalate effects that are 
specific to different types of underlying pathol-
ogy. Estrogen-related risk factors appear to vary 
by endometriosis that is concurrent with and 
independent of infertility (the latter which is 
often accompanied by pain) (Missmer et al. 
2004a, 2004b). However, in the absence of 
data on infertility and symptomatic pain, the 
findings reflect an averaged association of the 
phthalate measures with these two subgroups.
In addition to our study’s strengths in 
its exposure measurements, our study also 
benefited from its large sample size, its con-
sideration of several important potential 
confounders, and its representativeness of 
the general population of reproductive-age 
women living in the United States. In conclu-
sion, we have identified preliminary evidence 
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suggesting that exposure to DBP may be asso-
ciated with increased risk of endometriosis 
and uterine leiomyomata, and that exposure 
to DEHP may be associated with reduced risk 
of these conditions. These findings warrant 
investigation in future prospective studies.
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